Fortress Biotech reports 17.5% net revenue gain to $59.3M in 9M 2022; gets Nasdaq bid-price deficiency

Fortress Biotech, Inc.

2022-Q3 EPS reported -$0.68 revenue$59,339,000

Net revenue for nine months ended Sep 30, 2022 was $59.3M, up 17.5% from the same period in 2021.
Nasdaq notified Fortress that common stock bid price closed below $1.00 for 30 consecutive business days; compliance risk.
Journey Medical, a partner, generated Q3 2022 total revenue of $16.1M, down from $19.6M in Q3 2021.
Checkpoint Therapeutics approved a 1-for-10 reverse stock split; Avenue Therapeutics completed a 1-for-15 reverse split in Sep 2022.
Board declared monthly dividends of $0.1953125 per share on Series A Preferred Stock for Oct, Nov, Dec 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Fortress Biotech, Inc. reported the first nine months of 2022 results: revenue $59.3 million.

Period: the first nine months of 2022
Revenue: $59.3 million
Result: reported results

Exact text from the filing

Net revenue for the nine months of 2022 increased 17.5% period-over-period to $59.3 million

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Fortress Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-017843

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.